According to an amended 13D filing with the Securities and Exchange Commission, Nelson Obus and Joshua Landes‘ Wynnefield Capital decreased its stake in Omega Protein Corp (NYSE:OME) to 1.37 million shares, which represent 6.2% of the company’s outstanding shares. According to its 13F filing for the end of June, the stake previously consisted of 1.77 million common shares.
Omega Protein is a food business company that produces nutritious products and operates in two sectors: animal nutrition and human nutrition. Over the past 12 months, the company’s shares have gained 39.77%. For the second quarter of 2016, Omega Protein reported earnings per share of $0.62 and revenue of $112.7 million, compared to EPS of $0.43, and revenue of $93.2 million for the same period a year earlier. Earlier this month, DA Davidson boosted its price target on Omega Protein’s stock to $26 from $20, maintaining a ‘Neutral’ rating on it, while Wunderlich downgraded the stock to ‘Hold’ from ‘Buy’ but raised its price target on it to $26 from $22, and Pivotal Research boosted its price target to $30 from $25, and has a ‘Buy’ rating on the stock.
Investors in our database long Omega Protein Corp (NYSE:OME) at the end of June, aside from Wynnefield Capital, included Peter Algert and Kevin Coldiron’s Algert Coldiron Investors, with a position worth $874,000, Louis Navellier’s Navellier & Associates, which held a position valued at $284,000, and Gavin Saitowitz and Cisco J. Del Valle’s Springbok Capital. Some of the new investors in Omega Protein Corp (NYSE:OME) during the second quarter were Ken Griffin’s Citadel Investment Group, which had a $524,000 position in the company at the end of the period, and Robert B. Gillam’s McKinley Capital Management, which initiated a position worth $5,000 at the end of June.
Follow Omega Protein Corp (NYSE:OME)
Follow Omega Protein Corp (NYSE:OME)
You can access the original SEC filing by clicking here.
Ownership Summary Table
Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
---|---|---|---|---|---|---|
Wynnefield Partners Small Cap Value | 442,982 | 0 | 442,982 | 0 | 442,982 | 2.0% |
Wynnefield Partners Small Cap Value | 730,327 | 0 | 730,327 | 0 | 730,327 | 3.3% |
Wynnefield Small Cap Value Offshore Fund, Ltd. (No | 113,754 | 0 | 113,754 | 0 | 113,754 | 0.5% |
Wynnefield Capital, Inc. Profit Sharing Money Purchase Plan | 85,000 | 0 | 85,000 | 0 | 85,000 | 0.4% |
Wynnefield Capital Management | 1,173,309 | 0 | 1,173,309 | 0 | 1,173,309 | 5.3% |
Wynnefield Capital, Inc. 13-3688495 | 113,754 | 0 | 113,754 | 0 | 113,754 | 0.5% |
Nelson Obus | 0 | 1,372,063 | 0 | 1,372,063 | 1,372,063 | 6.2% |
Joshua Landes | 0 | 1,372,063 | 0 | 1,372,063 | 1,372,063 | 6.2% |
Follow Nelson Obus And Joshua Landes's Wynnefield Capital
Page 1 of 14 – SEC Filing
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D/A
(Amendment No. 7)
Under the Securities Exchange Act of 1934
OMEGA PROTEIN CORPORATION
(Name of Issuer)
Common Stock, $0.01 par value
(Title of Class of Securities)
68210P107
(CUSIP Number)
Wynnefield Partners Small Cap Value, L.P.
450 Seventh Avenue, Suite 509
New York, New York 10123
Attention: Mr. Nelson Obus
Copy to:
Jeffrey S. Tullman, Esq.
Kane Kessler, P.C.
1350 Avenue of the Americas, 26th Floor
New York, New York 10019
(212) 541-6222
(Name, Address and Telephone
Number of Person Authorized to Receive Notices and Communications)
August 11, 2016
(Date of Event which requires Filing of
this Statement)
If the filing person has previously filed
a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because
of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ¨
Follow Omega Protein Corp (NYSE:OME)
Follow Omega Protein Corp (NYSE:OME)
Page 2 of 14 – SEC Filing
CUSIP No. 68210P107 | 13D/A | Page 2 of 14 |
1 | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Wynnefield Partners Small Cap Value, L.P. 13-3688497 |
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨ (b) x |
3 | SEC USE ONLY |
4 | SOURCE OF FUNDS* WC |
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT ¨ |
6 | CITIZENSHIP OR PLACE OF ORGANIZATION Delaware |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 442,982 (See Item 5) |
8 | SHARED VOTING POWER 0 (See Item 5) | |
9 | SOLE DISPOSITIVE POWER 442,982 (See Item 5) | |
10 | SHARED DISPOSITIVE POWER 0 (See Item 5) |
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 442,982 (See Item 5) |
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN ¨ |
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 2.0% |
14 | TYPE OF REPORTING PERSON* PN |
Follow Omega Protein Corp (NYSE:OME)
Follow Omega Protein Corp (NYSE:OME)
Page 3 of 14 – SEC Filing
CUSIP No. 68210P107 | 13D/A | Page 3 of 14 |
1 | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Wynnefield Partners Small Cap Value, L.P. I 13-3953291 |
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨ (b) x |
3 | SEC USE ONLY |
4 | SOURCE OF FUNDS* WC |
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT ¨ |
6 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 730,327 (See Item 5) |
8 | SHARED VOTING POWER 0 (See Item 5) | |
9 | SOLE DISPOSITIVE POWER 730,327 (See Item 5) | |
10 | SHARED DISPOSITIVE POWER 0 (See Item 5) |
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 730,327 (See Item 5) |
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN ¨ |
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 3.3% |
14 | TYPE OF REPORTING PERSON*
PN |
Follow Omega Protein Corp (NYSE:OME)
Follow Omega Protein Corp (NYSE:OME)
Page 4 of 14 – SEC Filing
CUSIP No. 68210P107 | 13D/A | Page 4 of 14 |
1 | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Wynnefield Small Cap Value Offshore Fund, Ltd. (No IRS Identification |
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨ (b) x |
3 | SEC USE ONLY |
4 | SOURCE OF FUNDS* WC |
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT ¨ |
6 | CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 113,754 (See Item 5) |
8 | SHARED VOTING POWER 0 (See Item 5) | |
9 | SOLE DISPOSITIVE POWER 113,754 (See Item 5) | |
10 | SHARED DISPOSITIVE POWER 0 (See Item 5) |
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 113,754 (See Item 5) |
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN ¨ |
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.5% |
14 | TYPE OF REPORTING PERSON*
CO |
Follow Omega Protein Corp (NYSE:OME)
Follow Omega Protein Corp (NYSE:OME)
Page 5 of 14 – SEC Filing
CUSIP No. 68210P107 | 13D/A | Page 5 of 14 |
1 | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Wynnefield Capital, Inc. Profit Sharing & Money Purchase |
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨ (b) x |
3 | SEC USE ONLY |
4 | SOURCE OF FUNDS* N/A |
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT ¨ |
6 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 85,000 (See Item 5) |
8 | SHARED VOTING POWER 0 (See Item 5) | |
9 | SOLE DISPOSITIVE POWER 85,000 (See Item 5) | |
10 | SHARED DISPOSITIVE POWER 0 (See Item 5) |
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 85,000 (See Item 5) |
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN ¨ |
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.4% |
14 | TYPE OF REPORTING PERSON*
EP |
Follow Omega Protein Corp (NYSE:OME)
Follow Omega Protein Corp (NYSE:OME)
Page 6 of 14 – SEC Filing
CUSIP No. 68210P107 | 13D/A | Page 6 of 14 |
1 | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Wynnefield Capital Management, LLC 13-4018186 |
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨ (b) x |
3 | SEC USE ONLY |
4 | SOURCE OF FUNDS* N/A |
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT ¨ |
6 | CITIZENSHIP OR PLACE OF ORGANIZATION
New York |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 1,173,309 (See Item 5) |
8 | SHARED VOTING POWER 0 (See Item 5) | |
9 | SOLE DISPOSITIVE POWER 1,173,309 (See Item 5) | |
10 | SHARED DISPOSITIVE POWER 0 (See Item 5) |
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,173,309 (See Item 5) |
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN ¨ |
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 5.3% |
14 | TYPE OF REPORTING PERSON* OO |
Follow Omega Protein Corp (NYSE:OME)
Follow Omega Protein Corp (NYSE:OME)
Page 7 of 14 – SEC Filing
CUSIP No. 68210P107 | 13D/A | Page 7 of 14 |
1 | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Wynnefield Capital, Inc. 13-3688495 |
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨ (b) x |
3 | SEC USE ONLY |
4 | SOURCE OF FUNDS* N/A |
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT ¨ |
6 | CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 113,754 (See Item 5) |
8 | SHARED VOTING POWER 0 (See Item 5) | |
9 | SOLE DISPOSITIVE POWER 113,754 (See Item 5) | |
10 | SHARED DISPOSITIVE POWER 0 (See Item 5) |
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 113,754 (See Item 5) |
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN ¨ |
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 0.5% |
14 | TYPE OF REPORTING PERSON*
CO |
Follow Omega Protein Corp (NYSE:OME)
Follow Omega Protein Corp (NYSE:OME)
Page 8 of 14 – SEC Filing
CUSIP No. 68210P107 | 13D/A | Page 8 of 14 |
1 | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Nelson Obus |
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨ (b) x |
3 | SEC USE ONLY |
4 | SOURCE OF FUNDS* N/A |
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT ¨ |
6 | CITIZENSHIP OR PLACE OF ORGANIZATION United States |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 (See Item 5) |
8 | SHARED VOTING POWER 1,372,063 (See Item 5) | |
9 | SOLE DISPOSITIVE POWER 0 (See Item 5) | |
10 | SHARED DISPOSITIVE POWER 1,372,063 (See Item 5) |
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,372,063 (See Item 5) |
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN ¨ |
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.2% |
14 | TYPE OF REPORTING PERSON* IN |
Follow Omega Protein Corp (NYSE:OME)
Follow Omega Protein Corp (NYSE:OME)
Page 9 of 14 – SEC Filing
CUSIP No. 68210P107 | 13D/A | Page 9 of 14 |
1 | NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Joshua Landes |
2 | CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (See Instructions) (a) ¨ (b) x |
3 | SEC USE ONLY |
4 | SOURCE OF FUNDS* N/A |
5 | CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT ¨ |
6 | CITIZENSHIP OR PLACE OF ORGANIZATION
United States |
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH | 7 | SOLE VOTING POWER 0 (See Item 5) |
8 | SHARED VOTING POWER 1,372,063 (See Item 5) | |
9 | SOLE DISPOSITIVE POWER 0 (See Item 5) | |
10 | SHARED DISPOSITIVE POWER 1,372,063 (See Item 5) |
11 | AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,372,063 (See Item 5) |
12 | CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN ¨ |
13 | PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 6.2% |
14 | TYPE OF REPORTING PERSON*
IN |
Follow Omega Protein Corp (NYSE:OME)
Follow Omega Protein Corp (NYSE:OME)
Page 10 of 14 – SEC Filing
CUSIP No. 68210P107 | 13D/A | Page 10 of 14 |
Item 1. Security and Issuer.
This Amendment No. 7 amends the Statement
of Beneficial Ownership on Schedule 13D originally filed with the Securities and Exchange Commission (the “Commission”)
on August 11, 2015 and as amended by Amendment No. 1, filed on October 8, 2015, as further amended by Amendment No. 2, filed on
November 17, 2015, as further amended by Amendment No. 3, filed on March 1, 2016, as further amended by Amendment No. 4, filed
on March 30, 2016, as further amended by Amendment No. 5, filed on April 28, 2016 and as further amended by Amendment No. 6 filed
on May 24, 2016 (collectively, the “Schedule 13D”) by the Wynnefield Reporting Persons (as defined in the Schedule
13D) with respect to shares of common stock, $0.01 par value per share (the “Common Stock”) of Omega Protein Corporation,
a Nevada corporation (the “Issuer”). The Issuer maintains its principal executive office at 2105 City West Blvd., Suite
500, Houston, Texas 77042. Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the Schedule
13D.
Item 3. Source and Amount of Funds or
Other Consideration.
Item 3 of the Schedule 13D is hereby amended by the addition
of the following:
The securities reported in this Schedule
13D/A as directly beneficially owned by the Wynnefield Reporting Persons were `acquired with funds of approximately $17,598,967
(including brokerage commissions). All such funds were provided from the working capital or personal funds of the Wynnefield Reporting
Persons who directly beneficially own such securities.
Item 4. Purpose of the Transaction
Item 4 of the Schedule 13D is hereby amended by the addition
of the following:
This Schedule 13D is filed by the Wynnefield
Reporting Person to report disposition of shares of the Common Stock which decreases its beneficial ownership (as such term is
defined under Rule 13d-3 under the Exchange Act of 1934, as amended) of the Common Stock of the Issuer by more than 1% from the
amounts previously reported on Amendment No. 6 previously filed on May 24, 2016.
Item 5. Interest in Securities of the Issuer.
(a), (b) and (c) As of August 16, 2016,
the Wynnefield Reporting Persons beneficially owned in the aggregate 1,372,063 shares of Common Stock, constituting approximately
6.2% of the outstanding shares of Common Stock. The percentage of shares of Common Stock reported as being beneficially owned by
the Wynnefield Reporting Persons is based upon 22,305,073 shares outstanding as of July 29, 2016, as set forth in the Issuer’s
Quarterly Report on Form 10-Q for the quarter ended June 30, 2016, filed with the Commission on August 3, 2016.
The following table
sets forth certain information with respect to shares of Common Stock directly beneficially owned by the Wynnefield Reporting Persons
listed below:
Follow Omega Protein Corp (NYSE:OME)
Follow Omega Protein Corp (NYSE:OME)
Page 11 of 14 – SEC Filing
CUSIP No. 68210P107 | 13D/A | Page 11 of 14 |
Name | Number of Common Stock | Percentage of Outstanding Common Stock | ||||||
Wynnefield Partners | 442,982 | 2.0 | % | |||||
Wynnenfield Partners I | 730,327 | 3.3 | % | |||||
Wynnefield Offshore | 113,754 | 0.5 | % | |||||
Plan | 85,000 | 0.4 | % |
WCM is the sole general partner of Wynnefield
Partners and Wynnefield Partners I and, accordingly, may be deemed to be the indirect beneficial owner (as that term is defined
under Rule 13d-3 under the Exchange Act) of the Common Stock that Wynnefield Partners and Wynnefield Partners I beneficially own.
WCM, as the sole general partner of Wynnefield Partners and Wynnefield Partners I, has the sole power to direct the voting and
disposition of the Common Stock that Wynnefield Partners and Wynnefield Partners I beneficially own. Messrs. Obus and Landes are
the co-managing members of WCM and, accordingly, each of Messrs. Obus and Landes may be deemed to be the indirect beneficial owner
(as that term is defined under Rule 13d-3 under the Exchange Act) of the Common Stock that WCM may be deemed to beneficially own.
Each of Messrs. Obus and Landes, as co-managing members of WCM, share the power to direct the voting and disposition of the shares
of Common Stock that WCM may be deemed to beneficially own.
WCI is the sole investment
manager of Wynnefield Offshore and, accordingly, may be deemed to be the indirect beneficial owner (as that term is defined under
Rule 13d-3 under the Exchange Act) of the Common Stock that Wynnefield Offshore beneficially owns. WCI, as the sole investment
manager of Wynnefield Offshore, has the sole power to direct the voting and disposition of the Common Stock that Wynnefield Offshore
beneficially owns. Messrs. Obus and Landes are executive officers of WCI and, accordingly, each may be deemed to be the indirect
beneficial owner (as that term is defined under Rule 13d-3 under the Exchange Act) of the Common Stock that WCI may be deemed to
beneficially own. Messrs. Obus and Landes, as executive officers of WCI, share the power to direct the voting and disposition of
the shares of Common Stock that WCI may be deemed to beneficially own.
The Plan is an employee profit sharing
plan. Messrs. Obus and Landes are the co-trustees of the Profit Sharing Plan and accordingly, Messrs. Obus and Landes may be deemed
to be the indirect beneficial owner (as that term is defined under Rule 13d-3 under the Exchange Act) of the shares of Common Stock
that the Profit Sharing Plan may be deemed to beneficially own. Each of Messrs. Obus and Landes, as the trustees of the Plan, shares
with the other the power to direct the voting and disposition of the shares of Common Stock beneficially owned by the Plan.
Beneficial ownership of the Common Stock
shown on the cover pages of and set forth elsewhere in this Schedule 13D for each member of the Wynnefield Reporting Persons assumes
that they have not formed a group for purposes of Section 13(d)(3) under the Exchange Act, and Rule 13d-5(b)(1) promulgated thereunder.
If the members of the Wynnefield Reporting Persons were deemed to have formed a group for purposes of Section 13(d)(3) and Rule
13d-5(b)(1), the group would be deemed to own beneficially (and may be deemed to have shared voting and dispositive power over)
in the aggregate 1,372,063 shares of Common Stock, constituting approximately 6.2% of the outstanding shares of Common Stock. The
percentage of shares of Common Stock reported as being beneficially owned by the Wynnefield Reporting Persons is based upon 22,305,073
shares outstanding as of July 29, 2016, as set forth in the Issuer’s Quarterly Report on Form 10-Q for the quarter ended
June 30, 2016, filed with the Commission on August 3, 2016.
Follow Omega Protein Corp (NYSE:OME)
Follow Omega Protein Corp (NYSE:OME)
Page 12 of 14 – SEC Filing
CUSIP No. 68210P107 | 13D/A | Page 12 of 14 |
The filing of this Schedule 13D and any
future amendment by the Wynnefield Reporting Persons, and the inclusion of information herein and therein with respect to WCM,
WCI and Messrs. Obus and Landes, shall not be considered an admission that any of such persons, for the purpose of Section 16(b)
of the Exchange Act, are the beneficial owners of any shares in which such persons do not have a pecuniary interest. Each of WCM,
WCI and Messrs. Obus and Landes disclaims any beneficial ownership of the shares covered by this Schedule 13D.
The Wynnefield Reporting
Persons have acquired or sold shares of Common Stock during the last 60 days as follows:
Name | Transaction | Date | Number of Shares | Price Per Share | ||||||||
Wynnefield Partners | Purchase | 6/24/2016 | 906 | $ | 18.35 | |||||||
Wynnefield Partners | Purchase | 6/27/2016 | 3,677 | $ | 18.39 | |||||||
Wynnefield Partners | Sale | 8/4/2016 | 15,640 | $ | 25.00 | |||||||
Wynnefield Partners | Sale | 8/4/2016 | 8,097 | $ | 24.60 | |||||||
Wynnefield Partners | Sale | 8/5/2016 | 7,798 | $ | 24.52 | |||||||
Wynnefield Partners | Sale | 8/8/2016 | 15,390 | $ | 24.52 | |||||||
Wynnefield Partners | Sale | 8/9/2016 | 17,226 | $ | 24.55 | |||||||
Wynnefield Partners | Sale | 8/11/2016 | 33,524 | $ | 24.62 | |||||||
Wynnefield Partners | Sale | 8/12/2016 | 17,528 | $ | 24.50 | |||||||
Wynnefield Partners | Sale | 8/15/2016 | 8,538 | $ | 24.45 | |||||||
Wynnefield Partners I | Purchase | 6/24/2016 | 1,422 | $ | 18.35 | |||||||
Wynnefield Partners I | Purchase | 6/27/2016 | 5,776 | $ | 18.39 | |||||||
Wynnefield Partners I | Sale | 8/4/2016 | 12,704 | $ | 24.60 | |||||||
Wynnefield Partners I | Sale | 8/4/2016 | 24,540 | $ | 25.00 | |||||||
Wynnefield Partners I | Sale | 8/5/2016 | 12,226 | $ | 24.52 | |||||||
Wynnefield Partners I | Sale | 8/8/2016 | 24,147 | $ | 24.52 | |||||||
Wynnefield Partners I | Sale | 8/9/2016 | 27,010 | $ | 24.55 | |||||||
Wynnefield Partners I | Sale | 8/11/2016 | 52,566 | $ | 24.62 | |||||||
Wynnefield Partners I | Sale | 8/12/2016 | 27,483 | $ | 24.50 | |||||||
Wynnefield Partners I | Sale | 8/15/2016 | 13,381 | $ | 24.45 | |||||||
Wynnefield Offshore | Purchase | 6/24/2016 | 572 | $ | 18.35 | |||||||
Wynnefield Offshore | Purchase | 6/27/2016 | 2,333 | $ | 18.39 | |||||||
Wynnefield Offshore | Sale | 8/4/2016 | 9,820 | $ | 25.00 | |||||||
Wynnefield Offshore | Sale | 8/4/2016 | 5,084 | $ | 24.60 | |||||||
Wynnefield Offshore | Sale | 8/5/2016 | 4,891 | $ | 24.52 | |||||||
Wynnefield Offshore | Sale | 8/8/2016 | 9,663 | $ | 24.52 | |||||||
Wynnefield Offshore | Sale | 8/9/2016 | 10,764 | $ | 24.55 | |||||||
Wynnefield Offshore | Sale | 8/11/2016 | 20,947 | $ | 24.62 | |||||||
Wynnefield Offshore | Sale | 8/12/2016 | 10,952 | $ | 24.50 | |||||||
Wynnefield Offshore | Sale | 8/15/2016 | 5,340 | $ | 24.45 |
(d) and (e). Not Applicable.
Follow Omega Protein Corp (NYSE:OME)
Follow Omega Protein Corp (NYSE:OME)
Page 13 of 14 – SEC Filing
CUSIP No. 68210P107 | 13D/A | Page 13 of 14 |
SIGNATURE
After reasonable inquiry and to the best
of their knowledge and belief, the undersigned certify that the information set forth in this Schedule 13D is true, complete and
correct.
Dated: August 16, 2016 | ||
WYNNEFIELD PARTNERS SMALL CAP VALUE, L.P. I | ||
By: | Wynnefield Capital Management, LLC, | |
its General Partner | ||
By: | /s/ Nelson Obus | |
Nelson Obus, Co-Managing Member | ||
WYNNEFIELD PARTNERS SMALL CAP VALUE, L.P. | ||
By: | Wynnefield Capital Management, LLC, | |
its General Partner | ||
By: | /s/ Nelson Obus | |
Nelson Obus, Co-Managing Member | ||
WYNNEFIELD SMALL CAP VALUE OFFSHORE FUND, LTD. | ||
By: | Wynnefield Capital, Inc., | |
its Investment Manager | ||
By: | /s/ Nelson Obus | |
Nelson Obus, President | ||
WYNNEFIELD CAPITAL, INC. PROFIT SHARING & MONEY PURCHASE PLAN | ||
By: | /s/ Nelson Obus | |
Nelson Obus, Co-Trustee | ||
WYNNEFIELD CAPITAL MANAGEMENT, LLC | ||
By: | /s/ Nelson Obus | |
Nelson Obus, Co-Managing Member |
Follow Omega Protein Corp (NYSE:OME)
Follow Omega Protein Corp (NYSE:OME)
Page 14 of 14 – SEC Filing
CUSIP No. 68210P107 | 13D/A | Page 14 of 14 |
WYNNEFIELD CAPITAL, INC. | ||
By: | /s/ Nelson Obus | |
Nelson Obus, President | ||
/s/ Nelson Obus | ||
Nelson Obus, Individually | ||
/s/ Joshua Landes | ||
Joshua Landes, Individually |